MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • MDS Virtual Congress 2020

    Association between essential tremor, constipation, and the risk of developing Parkinson’s disease

    C. Reynolds, M. Gupta, M. Sandulescu (Danville, PA, USA)

    Objective: To evaluate the association between constipation and the risk of Parkinson’s disease (PD) in patients with a prior history of essential tremor (ET). Background:…
  • MDS Virtual Congress 2020

    Movement Disorders After Bariatric Surgeries – Case Series

    G. Fabiani, C.H Camargo, H. Teive (Curitiba, Brazil)

    Objective: Our objective is to report 6 cases series of MD after Bariatric surgeries (BS) and one case after hiatal surgery, with BS behavior. Background:…
  • MDS Virtual Congress 2020

    Attitudes of Care Partners Toward Medications for Parkinson’s Disease Psychosis

    S. Mantri, S. Albert, E. Klawson, L. Alzyoud, M. Daeschler, C. Kopil, C. Marras, L. Chahine (Toronto, ON, Canada)

    Objective: To explore attitudes regarding use of medications among care partners of individuals with Parkinson’s disease psychosis. Background: Parkinson’s disease (PD) psychosis is a highly…
  • MDS Virtual Congress 2020

    CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks

    A. Ellenbogen, A. Corbin, P. Zhao, D. Kegler-Ebo, H. Roberts (Bingham Farms, MI, USA)

    Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…
  • MDS Virtual Congress 2020

    Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts

    K. Marek, A. Siderowf, T. Simuni, C. Tanner (New Haven, CT, USA)

    Objective: The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes,…
  • MDS Virtual Congress 2020

    Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease

    J. Shirvan (Cambridge, MA, USA)

    Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…
  • MDS Virtual Congress 2020

    Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump

    M. Auffret, C. Geny, A. Lees, M. Vérin (Rennes, France)

    Objective: To describe the case of a parkinsonian patient treated by apomorphine pump who stopped smoking without difficulty despite being dependent to nicotine. To explore…
  • MDS Virtual Congress 2020

    Comparing the effects of rosemary and selegiline on behavioral symptoms of Parkinson’s animal model in mice

    M. Modaresi (Isfahan, Islamic Republic of Iran)

    Objective: Parkinson is from common disorders of central nervous system and the second disease in neurodegenerative diseases which occurs in 1% of people over the…
  • MDS Virtual Congress 2020

    Characterization of novel alpha-synuclein aggregation model of Parkinson’s disease

    A. Singh, S. Reunanen, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: To establish and characterize a robust alpha-synuclein (aSyn) aggregation pathology research model to allow efficient drug development platform for Parkinson's disease (PD). Background: PD…
  • MDS Virtual Congress 2020

    Decline in the midbrain-to-pons ratio over one year can support the differentiation between PSP and IPD

    S. Kannenberg, L. Dinkelbach, J. Caspers, A. Moldovan, S. Ferrea, M. Südmeyer, M. Butz, A. Schnitzler, C. Hartmann (Düsseldorf, Germany)

    Objective: The midbrain-to-pons ratio (MTPR) is considered as an important diagnostic biomarker to differentiate between progressive supranuclear palsy (PSP) and idiopathic Parkinson’s disease (IPD). Here,…
  • « Previous Page
  • 1
  • …
  • 100
  • 101
  • 102
  • 103
  • 104
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • #24475 (not found)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley